Stay updated with breaking news from Human Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Makana Therapeutics, a subsidiary of Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and...
Update: February, 26/2021 - 18:14 | A volunteer receives a dose of Nano Covax, Việt Nam's first COVID-19 vaccine, as the Phase 2 of the human trial begins at the Military Medical University on Friday. — VNA/VNS Photo Minh Quyết HÀ NỘI — A total of 74 volunteers were given the Vietnamese COVID-19 vaccine, Nano Covax, in phase II of human trials on Friday. Nanocovax is Việt Nam’s first COVID-19 vaccine reaching the human trial stage, developed by Nanogen Pharmaceutical Biotechnology JSC and the Military Medical University (M...
Second Vietnam-produced COVID-19 vaccine to begin human trials soon Chia sẻ | FaceBookTwitter Email Copy Link Copy link bài viết thành công 07/01/2021 10:09 GMT+7 The human trial of Vietnam’s COVID-19 vaccine will begin on January 21-22, Health Minister Nguyen Thanh Long has stated. Volunteers register to participate in NACOVAX trials COVIVAC has been developed by the Institute of Vaccines and Medical Biologicals (IVAC) based in the south-central province of Khanh Hoa. Vo...
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results December 14, 2020 05:00 ET | Source: Amarin Corporation plc Amarin Corporation plc Bedminster, New Jersey, UNITED STATES REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers VASCEPA COVID-19 CardioLink-9 Randomized Tri...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 ... Amarin Corporation plcDecember 13, 2020 GMT VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading dose VASCEPA administration resulted in a significant 52% reduct...